CAR T-Cell Therapy for Mantle-Cell Lymphoma

Chimeric antigen receptor (CAR) T-cell immunotherapy provides an important option for relapsed or refractory mantle-cell lymphoma (MCL). Investigators now report a multicenter, industry-sponsored, phase 1 study of lisocabtagene maraleucel (liso-cel) in patients whose MCL had progressed after two or more lines of therapy, including an anti-CD20 agent, an alkylator, and a Bruton tyrosine kinase inhibitor. Bridging therapy was permitted after leukapheresis; patients received lymphodepleting fludarabine plus cyclophosphamide for 3 days and then liso-cel infusions 2 to 7 days later (total dose, 50 or 100 x 10⁶ cells). Retreatment with liso-cel was permitted for patients who relapsed after complete remission.

Of the 104 patients who underwent leuk…